More low-income, first-generation students may instead go to community college, even if they were accepted to a four-year school, to help with family finances.

Campden BRI have begun a research project to evaluate how 3D printing could benefit the food industry.

The Federal Government's overhaul of billions of dollars in spending on Indigenous disadvantage is still only in the "early stages" of evaluation, five years after a funding shake-up that was found to be rushed and flawed.

Introduction: Gastrin Releasing peptide receptors (GRPRs) are potential molecular imaging targets in a variety of tumors. Recently, a ⁶⁸Ga-labelled antagonist to GRPRs, NeoBOMB1, was developed for PET. We report on the outcome of a Phase I/IIa clinical trial (EudraCT 2016-002053-38) within the EU-FP7 project Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with Metastatic Gastrointestinal Stromal Tumours (‘MITIGATE’) (grant agreement number 602306) in patients with oligometastatic gastrointestinal stromal tumors (GIST). Materials and Methods: The main objectives were evaluation of safety, biodistribution, dosimetry and preliminary tumor targeting of ⁶⁸Ga-NeoBOMB1 in patients with advanced TKI-treated GIST using PET/CT. Six patients with histologically confirmed GIST and unresectable primary or metastases undergoing an extended protocol for detailed pharmacokinetic analysis were included. ⁶⁸Ga-NeoBOMB1 was prepared using a kit procedure with a licensed ⁶⁸Ge/⁶⁸Ga generator. 3 MBq/kg body-weight were injected intravenously and safety parameters were assessed. PET/CT included dynamic imaging at 5 min, 11 min and 19 min as well as static imaging at 1, 2 and 3-4 h p.i. for dosimetry calculations. Venous blood samples and urine were collected for pharmacokinetics. Tumor targeting was assessed on a per-lesion and per-patient basis. Results: ⁶⁸Ga-NeoBOMB1 (50 µg) was prepared with high radiochemical purity (yield >97%). Patients received 174 ± 28 MBq of the radiotracer, which was well tolerated in all patients over a follow-up period of 4 weeks. Dosimetry calculations revealed a mean adsorbed effective dose of 0.029 ± 0.06 mSv/MBq with highest organ dose to the pancreas (0.274 ± 0.099 mSv/MBq). Mean plasma half-life was 27.3 min with primarily renal clearance (mean 25.7 ± 5.4% of injected dose 4h p.i.). Plasma metabolite analyses revealed high stability, metabolites were only detected in the urine. In three patients a significant uptake with increasing maximum standard uptake values (SUV_max at 2h p.i.: 4.3 to 25.9) over time was found in tumor lesions. Conclusion: This Phase I/IIa study provides safety data for ⁶⁸Ga-NeoBOMB1, a promising radiopharmaceutical for targeting GRPR-expressing tumors. Safety profiles and pharmacokinetics are suitable for PET imaging and absorbed dose estimates are comparable to other ⁶⁸Ga-labelled radiopharmaceuticals used in clinical routine.

OBJECTIVE

To assess the impact of a telemedicine visit using the platform Diabetic compared with a face-to-face visit on clinical outcomes, patients’ health-related quality of life (HRQoL), and physicians’ satisfaction in patients with type 1 diabetes.

OBJECTIVE

Topical oxygen has been used for the treatment of chronic wounds for more than 50 years. Its effectiveness remains disputed due to the limited number of robust high-quality investigations. The aim of this study was to assess the efficacy of multimodality cyclical pressure Topical Wound Oxygen (TWO2) home care therapy in healing refractory diabetic foot ulcers (DFUs) that had failed to heal with standard of care (SOC) alone.

Interferon beta, a drug originally developed to treat chronic obstructive pulmonary disease, or COPD, is being explored as a possible cure for the severe lung infections caused by COVID-19, media reports confirmed Monday

Bret Zeldow, Vincent Lo Re III, Jason Roy.

Source: The Annals of Applied Statistics, Volume 13, Number 3, 1989--2010.

Abstract:
Bayesian Additive Regression Trees (BART) is a flexible machine learning algorithm capable of capturing nonlinearities between an outcome and covariates and interactions among covariates. We extend BART to a semiparametric regression framework in which the conditional expectation of an outcome is a function of treatment, its effect modifiers, and confounders. The confounders are allowed to have unspecified functional form, while treatment and effect modifiers that are directly related to the research question are given a linear form. The result is a Bayesian semiparametric linear regression model where the posterior distribution of the parameters of the linear part can be interpreted as in parametric Bayesian regression. This is useful in situations where a subset of the variables are of substantive interest and the others are nuisance variables that we would like to control for. An example of this occurs in causal modeling with the structural mean model (SMM). Under certain causal assumptions, our method can be used as a Bayesian SMM. Our methods are demonstrated with simulation studies and an application to dataset involving adults with HIV/Hepatitis C coinfection who newly initiate antiretroviral therapy. The methods are available in an R package called semibart.

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen of the investigational antiviral remdesivir plus the anti-inflammatory drug baricitinib for coronavirus disease 2019 (COVID-19) has begun.

Intussusception is the most common cause of intestinal obstruction in young children. To date, there have been no prospective studies that have been able to develop a reliable clinical prediction model to determine which patients are at low risk for intussusception.

This study is the largest prospective cohort study to date to evaluate children with possible intussusception. It includes both univariate and multivariate analyses to develop clinical prediction models for patients at low risk for intussusception. (Read the full article)

Although follow-up examinations are recommended for suspected victims of sexual abuse or assault, little is known about the potential benefits of a second examination with regard to diagnosing trauma or sexually transmitted infections.

In ~23% of pediatric patients evaluated for sexual abuse or assault, a second examination by a specialist changed the interpretation of trauma likelihood or results in the detection of a sexually transmitted infection. (Read the full article)

Although it is known that relatively minor abusive injuries sometimes precede more severe physical abuse, the prevalence of these previous injuries in infants evaluated for abuse was not known.

A history of bruising or oral injury in a precruising infant evaluated for abuse should heighten the level of suspicion because these injuries are common in abused infants and rare in infants found not to be abused. (Read the full article)

The evaluation of blunt head trauma in children who undergo cranial computed tomography will occasionally reveal incidental findings. These findings may require further evaluation or intervention. The prevalence of incidental findings has previously been described using small cohorts, limiting generalizability.

This study is the largest pediatric multicenter description of the prevalence of incidental findings on cranial computed tomography. Incidental findings are categorized by urgency to describe the spectrum of abnormalities, providing a context for clinicians faced with these unexpected results. (Read the full article)

A case of M. leprae rifampicin resistance after irregular anti-leprosy treatments since 1971 is reported. Whole-genome sequencing from four longitudinal samples indicated relapse due to acquired rifampicin resistance and not to reinfection with another strain. A putative compensatory mutation in rpoC was also detected. Clinical improvement was achieved using an alternative therapy.

As we honor Mental Health Month, there are many calls to reduce suffering. Seems reasonable, right? It’s even in California’s Mental Health Services Act (MHSA), where public systems are called to “reduce subjective suffering.” And as we broadly focus more on outcomes in health, measuring suffering (and hopefully its reduction) [...]

The post Can we evaluate whole person suffering? appeared first on Government Data Connection.

Virtuoso Version -- IC6.1.7-64b.500.23

Cadence Spectre Version -- 17.10.515

I have a very simple circuit. Please find attached. It is basically a resistor across a port. I run a S-param simulation and can plot the S-params, but unfortunately not the Z-param or Y-param. 

/resized-image/__size/320x240/__key/communityserver-discussions-components-files/33/Capture_5F00_Sch.JPG

/resized-image/__size/320x240/__key/communityserver-discussions-components-files/33/Capture_5F00_Error.JPG

Can anyone point me in the correct direction to sort out this problem? The zpm does work in another design environment, but not in the new design environment (a new project). The virtuoso and the cadence-spectre versions match in both the project environments. I am at a loss at what to look for. 

In vitro approaches for predicting drug-drug interactions (DDIs) caused by alterations in transporter protein regulation are not well established. However, reports of transporter regulation via nuclear receptor (NR) modulation by drugs are increasing. This study examined alterations in transporter protein levels in sandwich-cultured human hepatocytes (SCHH; n = 3 donors) measured by liquid chromatography–tandem mass spectrometry–based proteomic analysis after treatment with N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-N-(2,2,2-trifluoroethyl)benzenesulfonamide (T0901317), the first described synthetic liver X receptor agonist. T0901317 treatment (10 μM, 48 hours) decreased the levels of organic cation transporter (OCT) 1 (0.22-, 0.43-, and 0.71-fold of control) and organic anion transporter (OAT) 2 (0.38-, 0.38-, and 0.53-fold of control) and increased multidrug resistance protein (MDR) 1 (1.37-, 1.48-, and 1.59-fold of control). The induction of NR downstream gene expression supports the hypothesis that T0901317 off-target effects on farnesoid X receptor and pregnane X receptor activation are responsible for the unexpected changes in OCT1, OAT2, and MDR1. Uptake of the OCT1 substrate metformin in SCHH was decreased by T0901317 treatment. Effects of decreased OCT1 levels on metformin were simulated using a physiologically-based pharmacokinetic (PBPK) model. Simulations showed a clear decrease in metformin hepatic exposure resulting in a decreased pharmacodynamic effect. This DDI would not be predicted by the modest changes in simulated metformin plasma concentrations. Altogether, the current study demonstrated that an approach combining SCHH, proteomic analysis, and PBPK modeling is useful for revealing tissue concentration–based DDIs caused by unexpected regulation of hepatic transporters by NR modulators.

Interrogate the data, consider possible incentives, and look for the dreaded “hype salad”

A recent survey from the George Washington University suggests that patients do not take social media into consideration when looking for a dermatologist and recommend that practitioners should use social media as a tool in engaging and educating patients.

It is estimated that one worker dies every 15 seconds from toxic exposures at work

With in-person visits with free agents restricted due to the coronavirus outbreak, some NFL agents are wondering how a new deal will become official without team examinations.

Money plays an important role in our lives. We have a lot of dreams, but short of funds that are needed to keep them alive.  So we have to focus our goals and choose which one is best to you. It is difficult to save the entire...

Three important steps can save your business for the future.

In a statement, PCB said that it was disappointed with Akhtar's "poor choice of words" and that Rizvi has initiated the proceedings at his own discretion.

A brainchild of the ECB, The Hundred will be 100-balls-per-side format and will be played by eight franchises rather than the established 18 first-class counties.

After the two repo rate cuts of 0.25 basis points each in February and April 2019, you may be looking forward to more affordable home loan financing. In general, your home loan EMIs will become cheaper to the extent that your

The answer sheets will be delivered to the teachers’ homes from 3,000 schools designated as exam centres.

Citing privacy and security concerns, Google has banned Zoom for its employees across offices, and promotes its own unified enterprise communication app Meets

Online Resource

Webinar information current as of October 9, 2008

When is the last time you really took stock of your HR strategy? Have you linked that strategy to your overall business plan? Do you have metrics in place to monitor its effectiveness? If your answers are shaky to any of these questions, your organization would benefit from some solid professional advice.

Learn how to:

• Audit your current HR strategy or plan
• Successfully link your HR strategy to the overall business strategy
• Analyze and prioritize areas for strategic improvement
• Develop a step by step plan for improvement of your HR strategy
• Present the case for strategic changes to your superiors
• Communicate the strategic changes to your organization
• Measure strategic improvement
• Make the connection between HR Strategy and return on investment

Speaker 

Tim McConnell, B.A, M.P.A., SPHR is a Senior HR Strategist with McConnell HR Consulting Inc. in Ottawa. He has over 25 years experience in Human Resources management, both as a Director of HR and as a senior HR consultant. Tim provides strategic HR guidance to senior executives and clients in the public, private and not-for-profit sectors.

He is a winner of the Ross A. Hennigar Memorial Award from HRPAO. He is the published author of several articles on HR management, Compensation and Organization Design. Tim is a past-President of the Ottawa Human Resources Professionals Association (OHRPA) and a past-President of HRPAO.

McConnell HRC provides services to clients in three key areas: Human Resources Strategy, Compensation and Organization Design.

Format

The following is required to access the archived webinar:

• Flash Player installed in your computer
• an Internet connection
• a sound card

This archived webinar will include:

• PowerPoint presentation with slides
• Speaker and facilitator voice-over presenting the slides and answering pre-recorded questions.

There is no time limitation in usage, you can play, pause and stop the presentation at your convenience.

If you would like more details about this product, or would like to order a copy online, please click here.

This webcast was recorded on March 25, 2008

Employee engagement is a real challenge in today's multi-generational organization, including yours. As an HR professional you must take employee engagement to the next level. A multi-generational engagement program that fits your organizational needs is critical. Achieve higher productivity, motivation, and retention by understanding, developing and maintaining employee engagement in the new workforce. Purchase this archived webinar and gain the essential tools and practical strategies required to understand your organization's generational mix, develop a multi-generational engagement program, and implement your program effectively.

Agenda 

• Understand and define the different generations in your organization
• Engage each of the four generations
• Identify the influencers of engagement of your organization's generational mix
• Evaluate existing HR practices for engagement across the generations in your organization
• Jump-start engagement across different generations by tailoring your HR strategies to your company's generational mix
• Present the case for a multi-generational employee engagement program

Format
Participate right from your desk or office. All you need is an Internet connection and a sound card.

This archived webinar will include:

• PowerPoint presentation with slides
• Speaker and facilitator voice-over presenting the slides and answering pre-recorded questions

The Speaker
Barbara Adams, CHRP, BA, is a senior business executive with over 20 years' experience within the human resources field. As Managing Director of HR architects, she provides business consulting mainly in the creative implementation of human resources strategies, objectives, and processes; the facilitation of strategic planning, workshops, and management retreats; and the design of people-oriented workplace practices. She also provides ongoing human resources consulting on a contract basis.

Previously the Vice-President of Human Resources for one of the 50 best employers in Canada, Barbara is a Certified Human Resources Professional, a Certified Chief Executive, a Certified Compensation Professional and holds a BA in Business Administration (Entrepreneurial Leadership). She is past Chair of the Fraser Valley Advisory Council for the BC Human Resources Management Association, instructor of Human Resources Management for Langara College in the Business Administration Certificate Program, and instructor of Operating the Small Business in the Small Business Management Certificate Program.

If you would like more details about this product, or would like to order a copy online, please click here.